Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Introgen Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: zeta1961 who wrote (732)	6/4/2007 12:32:16 PM
From: Jibacoa	Read Replies (1) \| Respond to of 802

Not too much help for the stock with today's announcement.<g> Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer Monday June 4, 8:00 am ET Final Results from Phase 2 Trial Presented at Major Cancer Conference CHICAGO--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ: INGN - News) reported positive final data from a Phase 2 clinical trial of INGN 225 in patients with small cell lung cancer (SCLC) at the annual meeting of the American Society of Clinical Oncology in Chicago. In the 43 patients evaluable for survival following INGN 225 treatment, survival was superior to historical controls and five patients remain progression free from 378 to 894 days following vaccination with INGN 225. INGN 225 is an immunotherapy (vaccine) that utilizes an adenovector to deliver the p53 gene to a patient's immune cells, stimulating an anti-tumor immune response. Data from an expanded number of patients confirmed previous findings that INGN 225 induces anti-tumor immune responses with higher than expected responses to subsequent chemotherapy. Positive immune responses to INGN 225 were observed in 42 percent of evaluable patients. Of those with positive immune responses, 78.6 percent responded to chemotherapy compared with only 33 percent of those without immune responses. The association of INGN 225 immune responses with increased responses to subsequent chemotherapy was statistically significant (p=0.01). The tumor response rate in patients with platinum-resistant disease who received chemotherapy following INGN 225 was 45 percent, which compares very favorably with a historical response rate of less than 15 percent in these patients. Interim data from this trial were previously published in Clinical Cancer Research. "Our updated data suggest that INGN 225 followed by chemotherapy can have a positive impact on these patients' clinical outcomes and continue to support that INGN 225 significantly enhances response to post-vaccination chemotherapy," said Robert E. Sobol, M.D., Introgen's senior vice president of Medical and Scientific Affairs. "We are particularly encouraged by the response rate in patients with platinum-resistant disease who have very few effective treatment options." Snip Bernard